Managed Account Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Managed Account Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$42.7M	Sell	312,238 -87,697	-22%	-$10.9M	0.04%	450
2015 Q1	$49.8M	Sell	399,935 -127,204	-24%	-$13.5M	0.04%	408
2014 Q4	$47.7M	Sell	527,139 -16,383	-3%	-$1.36M	0.05%	411
2014 Q3	$39.2M	Sell	543,522 -318,358	-37%	-$20.9M	0.04%	447
2014 Q2	$53.6M	Sell	861,880 -477,643	-36%	-$28.9M	0.06%	354
2014 Q1	$91.4M	Buy	1,339,523 +410,825	+44%	+$30.3M	0.12%	209
2013 Q4	$65.3M	Buy	928,698 +243,904	+36%	+$16.6M	0.09%	270
2013 Q3	$49.4M	Buy	684,794 +161,390	+31%	+$10.7M	0.07%	308
2013 Q2	$29.2M	Buy	+523,404	New	+$32.6M	0.05%	437

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Managed Account Advisors's BMRN Position: Q2 2015 in Review

Managed Account Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q2 2015, selling an estimated $10.9M and leaving 312,238 shares worth $42.7M. The position accounts for 0.04% of the portfolio, ranked #450.

Managed Account Advisors first reported a position in BMRN in Q2 2013 and has held it in 9 quarters since. The position peaked at $91.4M in Q1 2014. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Managed Account Advisors held 312,238 shares of BioMarin Pharmaceuticals worth $42.7M as of Q2 2015.
Managed Account Advisors sold 87,697 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $10.9M.
BioMarin Pharmaceuticals made up 0.04% of Managed Account Advisors's portfolio in Q2 2015, its #450 holding.
Managed Account Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's BioMarin Pharmaceuticals position peaked at $91.4M in Q1 2014.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.